WO2002081496A2 - Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores - Google Patents
Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores Download PDFInfo
- Publication number
- WO2002081496A2 WO2002081496A2 PCT/CU2002/000003 CU0200003W WO02081496A2 WO 2002081496 A2 WO2002081496 A2 WO 2002081496A2 CU 0200003 W CU0200003 W CU 0200003W WO 02081496 A2 WO02081496 A2 WO 02081496A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibody
- antibody
- constant region
- human
- antibodies
- Prior art date
Links
- 150000002270 gangliosides Chemical class 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title claims description 8
- 206010028980 Neoplasm Diseases 0.000 title abstract description 19
- 238000003745 diagnosis Methods 0.000 title abstract description 7
- 241001529936 Murinae Species 0.000 claims abstract description 43
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 16
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 16
- 230000003302 anti-idiotype Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 206010027476 Metastases Diseases 0.000 claims description 8
- 229940072221 immunoglobulins Drugs 0.000 claims description 8
- 201000010893 malignant breast melanoma Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 3
- 230000002163 immunogen Effects 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract description 2
- 230000035772 mutation Effects 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- 239000013598 vector Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 9
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 239000006152 selective media Substances 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- -1 GD3 ganglioside Chemical class 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 4
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 4
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 4
- 229960000951 mycophenolic acid Drugs 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 102000048429 human PAG1 Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940060155 neuac Drugs 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001130 anti-lysozyme effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/473,977 US20040253233A1 (en) | 2001-04-06 | 2002-04-08 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors |
MXPA03008739A MXPA03008739A (es) | 2001-04-06 | 2002-04-08 | Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores. |
SK1226-2003A SK287914B6 (sk) | 2001-04-06 | 2002-04-08 | Chimeric monoclonal antibody and its use in the preparation of medicament for the treatment of malignant tumors, cell line and pharmaceutical composition |
BRPI0208676A BR0208676B1 (pt) | 2001-04-06 | 2002-04-08 | Chemical monoclonal antibody, pharmaceutical composition, and, use of a monoclonal antibody |
DE60223547T DE60223547T2 (de) | 2001-04-06 | 2002-04-08 | Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren |
CA2441845A CA2441845C (en) | 2001-04-06 | 2002-04-08 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
NZ528599A NZ528599A (en) | 2001-04-06 | 2002-04-08 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors |
AU2002308348A AU2002308348B2 (en) | 2001-04-06 | 2002-04-08 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
KR1020037012969A KR100946168B1 (ko) | 2001-04-06 | 2002-04-08 | 강글리오사이드-관련 재조합 항체 및 종양의 진단 및치료에 있어서 이의 용도 |
EA200301098A EA006310B1 (ru) | 2001-04-06 | 2002-04-08 | Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей |
DK02759752T DK1411064T3 (da) | 2001-04-06 | 2002-04-08 | Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer |
SI200230660T SI1411064T1 (sl) | 2001-04-06 | 2002-04-08 | Rekombinantna protitelesa v povezavi z gangliozidi in njihova uporaba pri diagnozi in zdravljenju tumorjev |
HU0401695A HU228105B1 (en) | 2001-04-06 | 2002-04-08 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
EP02759752A EP1411064B1 (en) | 2001-04-06 | 2002-04-08 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
JP2002579482A JP2004528033A (ja) | 2001-04-06 | 2002-04-08 | ガングリオシド関連組換え抗体及び腫瘍の診断及び治療への使用 |
UA2003108989A UA75393C2 (en) | 2001-04-06 | 2002-08-04 | Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it |
IS6965A IS6965A (is) | 2001-04-06 | 2003-09-23 | Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum |
BG108228A BG66304B1 (bg) | 2001-04-06 | 2003-10-03 | Рекомбинантни антитела, свързващи ганглиозид и тяхното използване при диагностициране и лечение на тумори |
NO20034437A NO20034437L (no) | 2001-04-06 | 2003-10-03 | Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer |
HR20030805A HRP20030805B1 (en) | 2001-04-06 | 2003-10-06 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
HK05102752A HK1070080A1 (en) | 2001-04-06 | 2005-04-01 | Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors |
AU2007231687A AU2007231687B2 (en) | 2001-04-06 | 2007-10-26 | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors |
US12/407,046 US8758753B2 (en) | 2001-04-06 | 2009-03-19 | Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU84/2001 | 2001-04-06 | ||
CU2001008420010084A CU23007A1 (es) | 2001-04-06 | 2001-04-06 | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10473977 A-371-Of-International | 2002-04-08 | ||
US12/407,046 Division US8758753B2 (en) | 2001-04-06 | 2009-03-19 | Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002081496A2 true WO2002081496A2 (es) | 2002-10-17 |
WO2002081496A3 WO2002081496A3 (es) | 2004-02-19 |
Family
ID=40291118
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2002/000002 WO2002081661A2 (es) | 2001-04-06 | 2002-04-08 | Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos |
PCT/CU2002/000003 WO2002081496A2 (es) | 2001-04-06 | 2002-04-08 | Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2002/000002 WO2002081661A2 (es) | 2001-04-06 | 2002-04-08 | Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos |
Country Status (37)
Country | Link |
---|---|
US (3) | US20050069535A1 (es) |
EP (3) | EP1411064B1 (es) |
JP (2) | JP2004528033A (es) |
KR (3) | KR100863509B1 (es) |
CN (3) | CN100349920C (es) |
AR (2) | AR033123A1 (es) |
AT (3) | ATE378356T1 (es) |
AU (3) | AU2002308348B2 (es) |
BG (2) | BG66293B1 (es) |
BR (3) | BR0208675A (es) |
CA (2) | CA2443372C (es) |
CU (1) | CU23007A1 (es) |
CZ (2) | CZ296276B6 (es) |
DE (2) | DE60228561D1 (es) |
DK (2) | DK1411064T3 (es) |
EA (2) | EA006936B1 (es) |
EC (2) | ECSP034787A (es) |
ES (2) | ES2312610T3 (es) |
HK (3) | HK1066818A1 (es) |
HR (2) | HRP20030806B1 (es) |
HU (2) | HU228106B1 (es) |
IL (2) | IL158246A0 (es) |
IS (2) | IS2701B (es) |
MX (2) | MXPA03008739A (es) |
MY (3) | MY157372A (es) |
NO (2) | NO331533B1 (es) |
NZ (2) | NZ528599A (es) |
PE (1) | PE20020972A1 (es) |
PL (2) | PL208109B1 (es) |
PT (2) | PT1411064E (es) |
SG (1) | SG161737A1 (es) |
SI (2) | SI1411064T1 (es) |
SK (2) | SK287783B6 (es) |
UA (3) | UA75393C2 (es) |
UY (2) | UY27242A1 (es) |
WO (2) | WO2002081661A2 (es) |
ZA (2) | ZA200307585B (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
EA015629B1 (ru) * | 2005-08-11 | 2011-10-31 | Арпи Матоссиан-Роджерс | Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний |
US8809005B2 (en) | 2006-11-21 | 2014-08-19 | Hoffmann-La Roche Inc. | Conjugate and its use as a standard in an immunoassay |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1853305T3 (en) * | 2005-02-04 | 2014-12-01 | Survac Aps | Survivin-peptide vaccine |
FI20055398A0 (fi) * | 2005-07-08 | 2005-07-08 | Suomen Punainen Risti Veripalv | Menetelmä solupopulaatioiden evaluoimiseksi |
CN103450359B (zh) | 2005-08-19 | 2018-07-24 | 惠氏有限责任公司 | 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途 |
ITFI20060163A1 (it) * | 2006-06-29 | 2006-09-28 | Menarini Internat Operations Luxembourg Sa | Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio |
WO2009104649A1 (ja) * | 2008-02-22 | 2009-08-27 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
EP2166085A1 (en) | 2008-07-16 | 2010-03-24 | Suomen Punainen Risti Veripalvelu | Divalent modified cells |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
JP6061469B2 (ja) | 2009-03-10 | 2017-01-25 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗bcma抗体 |
CN102471380B (zh) | 2009-04-01 | 2015-01-14 | 霍夫曼-拉罗奇有限公司 | 抗FcRH5抗体和免疫偶联物及使用方法 |
CU23736A1 (es) * | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
CA2780713A1 (en) * | 2009-09-03 | 2011-03-10 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
US9469685B2 (en) * | 2011-01-10 | 2016-10-18 | Emory University | Antibodies directed against influenza |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
EP2641916A1 (en) * | 2012-03-23 | 2013-09-25 | Centre National de la Recherche Scientifique (C.N.R.S) | Novel antibodies anti-sPLA2-IIA and uses thereof |
EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
PL3192812T3 (pl) | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
AU2015243246B2 (en) * | 2014-04-10 | 2018-09-06 | Obi Pharma Inc. | Antibodies, pharmaceutical compositions and uses thereof |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
IL256079B2 (en) | 2015-06-16 | 2024-01-01 | Genentech Inc | Human antibodies with improved affinity to FCRH5 - and methods of use |
WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0657471A1 (en) * | 1993-12-09 | 1995-06-14 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
EP0699755A2 (en) * | 1994-06-30 | 1996-03-06 | Centro de Inmunologia Molecular | Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them |
US5589573A (en) * | 1993-10-06 | 1996-12-31 | Yoshihide Hagiwara | Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences |
US6207815B1 (en) * | 1988-10-19 | 2001-03-27 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2754206B2 (ja) * | 1987-11-17 | 1998-05-20 | メクト株式会社 | α2→3結合を認識するモノクローナル抗体 |
ES2144440T3 (es) * | 1992-08-18 | 2000-06-16 | Centro Inmunologia Molecular | Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen. |
US6063379A (en) * | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
CU22702A1 (es) * | 1997-10-21 | 2001-07-31 | Centro Inmunologia Molecular | Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
-
2001
- 2001-04-06 CU CU2001008420010084A patent/CU23007A1/es unknown
-
2002
- 2002-04-05 MY MYPI20021239A patent/MY157372A/en unknown
- 2002-04-05 MY MYPI20021228A patent/MY137078A/en unknown
- 2002-04-05 AR ARP020101264A patent/AR033123A1/es not_active Application Discontinuation
- 2002-04-05 UY UY27242A patent/UY27242A1/es not_active Application Discontinuation
- 2002-04-05 UY UY27243A patent/UY27243A1/es unknown
- 2002-04-05 MY MYPI20081190A patent/MY145703A/en unknown
- 2002-04-05 AR ARP020101263A patent/AR033122A1/es unknown
- 2002-04-08 US US10/473,978 patent/US20050069535A1/en not_active Abandoned
- 2002-04-08 BR BR0208675-1A patent/BR0208675A/pt not_active IP Right Cessation
- 2002-04-08 PT PT02759752T patent/PT1411064E/pt unknown
- 2002-04-08 JP JP2002579482A patent/JP2004528033A/ja active Pending
- 2002-04-08 DE DE60228561T patent/DE60228561D1/de not_active Expired - Lifetime
- 2002-04-08 IL IL15824602A patent/IL158246A0/xx unknown
- 2002-04-08 PT PT02759751T patent/PT1384726E/pt unknown
- 2002-04-08 EP EP02759752A patent/EP1411064B1/en not_active Expired - Lifetime
- 2002-04-08 SK SK1216-2003A patent/SK287783B6/sk not_active IP Right Cessation
- 2002-04-08 SG SG200506530-5A patent/SG161737A1/en unknown
- 2002-04-08 CN CNB028086309A patent/CN100349920C/zh not_active Expired - Fee Related
- 2002-04-08 AU AU2002308348A patent/AU2002308348B2/en not_active Ceased
- 2002-04-08 US US10/473,977 patent/US20040253233A1/en not_active Abandoned
- 2002-04-08 NZ NZ528599A patent/NZ528599A/en not_active IP Right Cessation
- 2002-04-08 DK DK02759752T patent/DK1411064T3/da active
- 2002-04-08 CA CA2443372A patent/CA2443372C/en not_active Expired - Fee Related
- 2002-04-08 SI SI200230660T patent/SI1411064T1/sl unknown
- 2002-04-08 EA EA200301097A patent/EA006936B1/ru not_active IP Right Cessation
- 2002-04-08 SK SK1226-2003A patent/SK287914B6/sk not_active IP Right Cessation
- 2002-04-08 EP EP02759751A patent/EP1384726B1/en not_active Expired - Lifetime
- 2002-04-08 ES ES02759751T patent/ES2312610T3/es not_active Expired - Lifetime
- 2002-04-08 PE PE2002000283A patent/PE20020972A1/es not_active Application Discontinuation
- 2002-04-08 DE DE60223547T patent/DE60223547T2/de not_active Expired - Lifetime
- 2002-04-08 WO PCT/CU2002/000002 patent/WO2002081661A2/es active IP Right Grant
- 2002-04-08 AU AU2002308347A patent/AU2002308347B2/en not_active Ceased
- 2002-04-08 AT AT02759752T patent/ATE378356T1/de active
- 2002-04-08 DK DK02759751T patent/DK1384726T3/da active
- 2002-04-08 BR BRPI0208675-1A patent/BRPI0208675B1/pt unknown
- 2002-04-08 AT AT06076643T patent/ATE477279T1/de not_active IP Right Cessation
- 2002-04-08 WO PCT/CU2002/000003 patent/WO2002081496A2/es active Application Filing
- 2002-04-08 BR BRPI0208676A patent/BR0208676B1/pt not_active IP Right Cessation
- 2002-04-08 NZ NZ528598A patent/NZ528598A/en not_active IP Right Cessation
- 2002-04-08 CN CNB028084330A patent/CN1319991C/zh not_active Expired - Fee Related
- 2002-04-08 EA EA200301098A patent/EA006310B1/ru not_active IP Right Cessation
- 2002-04-08 KR KR1020037012938A patent/KR100863509B1/ko not_active IP Right Cessation
- 2002-04-08 HU HU0401355A patent/HU228106B1/hu not_active IP Right Cessation
- 2002-04-08 PL PL371937A patent/PL208109B1/pl unknown
- 2002-04-08 MX MXPA03008739A patent/MXPA03008739A/es active IP Right Grant
- 2002-04-08 SI SI200230766T patent/SI1384726T1/sl unknown
- 2002-04-08 ES ES02759752T patent/ES2296986T3/es not_active Expired - Lifetime
- 2002-04-08 HU HU0401695A patent/HU228105B1/hu not_active IP Right Cessation
- 2002-04-08 CZ CZ20032641A patent/CZ296276B6/cs not_active IP Right Cessation
- 2002-04-08 JP JP2002580025A patent/JP4366080B2/ja not_active Expired - Fee Related
- 2002-04-08 CA CA2441845A patent/CA2441845C/en not_active Expired - Fee Related
- 2002-04-08 EP EP06076643A patent/EP1798243B1/en not_active Expired - Lifetime
- 2002-04-08 PL PL02371770A patent/PL371770A1/xx not_active Application Discontinuation
- 2002-04-08 MX MXPA03008738A patent/MXPA03008738A/es not_active Application Discontinuation
- 2002-04-08 AT AT02759751T patent/ATE406386T1/de active
- 2002-04-08 KR KR1020037012969A patent/KR100946168B1/ko not_active IP Right Cessation
- 2002-04-08 CZ CZ2003-2668A patent/CZ304424B6/cs not_active IP Right Cessation
- 2002-04-08 CN CN2007101021039A patent/CN101054417B/zh not_active Expired - Fee Related
- 2002-08-04 UA UA2003108989A patent/UA75393C2/uk unknown
- 2002-08-04 UA UA2003108988A patent/UA76745C2/uk unknown
-
2003
- 2003-09-23 IS IS6964A patent/IS2701B/is unknown
- 2003-09-23 IS IS6965A patent/IS6965A/is unknown
- 2003-09-29 ZA ZA200307585A patent/ZA200307585B/en unknown
- 2003-09-30 EC EC2003004787A patent/ECSP034787A/es unknown
- 2003-09-30 EC EC2003004788A patent/ECSP034788A/es unknown
- 2003-10-01 ZA ZA2003/07679A patent/ZA200307679B/en unknown
- 2003-10-02 IL IL158246A patent/IL158246A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034436A patent/NO331533B1/no not_active IP Right Cessation
- 2003-10-03 BG BG108227A patent/BG66293B1/en unknown
- 2003-10-03 NO NO20034437A patent/NO20034437L/no not_active Application Discontinuation
- 2003-10-03 BG BG108228A patent/BG66304B1/bg unknown
- 2003-10-06 HR HR20030806A patent/HRP20030806B1/xx not_active IP Right Cessation
- 2003-10-06 HR HR20030805A patent/HRP20030805B1/xx not_active IP Right Cessation
-
2004
- 2004-12-14 HK HK04109894A patent/HK1066818A1/xx not_active IP Right Cessation
-
2005
- 2005-04-01 HK HK05102752A patent/HK1070080A1/xx not_active IP Right Cessation
- 2005-12-20 UA UAA200512270A patent/UA86768C2/ru unknown
-
2007
- 2007-10-26 AU AU2007231687A patent/AU2007231687B2/en not_active Expired - Fee Related
- 2007-12-31 HK HK07114311.6A patent/HK1109160A1/xx not_active IP Right Cessation
-
2008
- 2008-08-07 KR KR1020087019420A patent/KR100919617B1/ko not_active IP Right Cessation
-
2009
- 2009-03-19 US US12/407,046 patent/US8758753B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207815B1 (en) * | 1988-10-19 | 2001-03-27 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
US5589573A (en) * | 1993-10-06 | 1996-12-31 | Yoshihide Hagiwara | Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences |
EP0657471A1 (en) * | 1993-12-09 | 1995-06-14 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
EP0699755A2 (en) * | 1994-06-30 | 1996-03-06 | Centro de Inmunologia Molecular | Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them |
Non-Patent Citations (4)
Title |
---|
GEORGE P. SMITH: "Sequence of the full-lenght immunoglobulin kappa-chain of mouse myeloma MPC 11." BIOCHEMISTRY JOURNAL, vol. 171, no. 2, 1978, pages 337-347, XP002902758 * |
HUANG D.-B. ET AL: "Comparison of crystal structures of two homologous proteins: Structural origin of altered domain interactions in immunoglobulin light-chain dimers." BIOCHEMISTRY, vol. 33, no. 49, 1994, pages 14848-14857, XP002902756 * |
KAVALER J ET AL: "A set of closely related antibodies dominates the primary antibody response to the antigenic site CB of the A/PR/8/34 influenza virus hemagglutinin." THE JOURNAL OF IMMUNOLOGY, vol. 145, no. 7, 1 October 1990 (1990-10-01), pages 2312-2321, XP002902757 ISSN: 0022-1767 * |
PEREZ A ET AL: "Immunogenetic analysis of variable regions encoding AB1 and gamma-Type AB2 antibodies from the NeuGc-containing ganglioside family." HYBRIDOMA, vol. 20, no. 4, 2001, pages 211-221, XP002902755 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
EA015629B1 (ru) * | 2005-08-11 | 2011-10-31 | Арпи Матоссиан-Роджерс | Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний |
US9243062B2 (en) | 2005-08-11 | 2016-01-26 | Arpi Matossian-Rogers | Peptides for treatment and diagnosis of autoimmune disease |
US8809005B2 (en) | 2006-11-21 | 2014-08-19 | Hoffmann-La Roche Inc. | Conjugate and its use as a standard in an immunoassay |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8758753B2 (en) | Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors | |
EP1623997B1 (en) | Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours | |
US20210395369A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof in cell therapy | |
JP5795538B2 (ja) | ヒトのラミニン5アルファ3鎖のlg4−5ドメインに対するモノクローナル抗体 | |
KR20030083698A (ko) | 물질 | |
TWI714854B (zh) | 抗globo h之人類化抗體及其於治療癌症之用途 | |
JP7392200B2 (ja) | グリコシル化ceacam5に特異的に結合した抗体 | |
WO2001036485A2 (es) | Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2441845 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/008739 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1552/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/07585 Country of ref document: ZA Ref document number: 200307585 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 03086749A Country of ref document: CO Ref document number: 03086749 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-2668 Country of ref document: CZ Ref document number: 528599 Country of ref document: NZ Ref document number: CR2003-007091 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12262003 Country of ref document: SK Ref document number: 1020037012969 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 10822802 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20030805A Country of ref document: HR Ref document number: 2002579482 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002759752 Country of ref document: EP Ref document number: 028086309 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200301098 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002308348 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10473977 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002759752 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-2668 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 528599 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002759752 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2002308348 Country of ref document: AU Date of ref document: 20020408 Kind code of ref document: B |
|
ENP | Entry into the national phase |
Ref document number: PI0208676 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087019420 Country of ref document: KR |